its shareholder, Shenzhen baozhilin company, was also sued by Kwan Tak-hing pharmaceutical bureau and hong kong baozhilin company, claiming that Shenzhen baozhilin fraudulently used the "baozhilin" trademark, infringing intellectual property rights and reputation rights.